Kornimate/medical-research-clean huggingface dataset:
lille study for childhood health promotion

Conditions: Overweight, Infant; Overweight and Obesity; Overweight, Childhood

Summary: obesity could be avoided but once declared it become a chronic disease with numerous health complications, including cardiovascular and metabolic diseases, cancers, and finally a loss of life expectancy. considering that after the age of 6 years old, half of the obese children will become obese adults, the who has been declared childhood obesity prevention as a health priority area. large-scale prevention of obesity is challenging and it would be more efficient to proceed to early identification of high risks children to implement personalized prevention. the elipse study main objective is to evaluate the efficacy of personalized multidisciplinary care to reduce the bmi of overweight or obese children. a 2 years educational program will be evaluated at short and longer terms (after a 12 months follow-up), and its benefits will also be assessed based on comparison with a historical control group. along with efficacy evaluation, scientific objectives were designed to investigate clinical, genetic, social, and behavioural risk factors and to analyse potential correlations between these factors and a predisposition to overweight or obesity. moreover, advanced analyses will be performed to decipher the impact of diverse risk profiles on the efficacy of the educational program. the motive of the elipse study is to promote the health and well-being of children and their families to tackle the health burden represented by childhood overweight and obesity. combined with innovative scientific objectives, this study ambitions to develop more efficient and more personalized preventive care methods.


Eligibility criteria:
inclusion criteria: * children from the first year of primary school in lille city * overweight or obese children as defined by the iotf and/or with at least one of the following risk factors: 1) early adiposity rebound (before 6 years old), 2) an upward crossing of major percentiles on the bmi curve (after 6 years old). * children whose legal tutor(s) is(are) able to understand the enlightened information. * children whose legal tutor(s) has(ve) signed the free and informed consent. exclusion criteria: * refusal from children or their tutors to participate in the study. * impossibility to participate in the study in its totality. * pathology known to impact the bmi: follow-up care for eating behaviour problems, endocrine disorders (hypercorticism, hypothyroidism, growth factor deficiency, hypothalamic-hypophysis lesions), genetic disorders (prader willi syndrome, bardet-biedl syndrome), drugs that affect body weight (antidepressant, neuroleptics, corticoids). * previous participation in a similar educational program.

Keywords: paediatric overweight and obesity childhood obesity personalized prevention and medicine educational program genetic of obesity
sintilimab combined with bevacizumab and liver protective support therapy in unresectable hepatocellular carcinoma

Conditions: Hepatocellular Carcinoma

Summary: to evaluate the efficacy and safety of sintilimab combined with bevacizumab and liver protective support therapy in child-pugh b and/or ecog ps 2 unresectable hepatocellular carcinoma


Eligibility criteria:
inclusion criteria: * advanced unresectable hepatocellular carcinoma confirmed by histology or cytology * age 20-79 * at least one measurable lesion defined in recist version 1.1 * child pugh grade b * ecog ps score 2 * the expected life is at least 90 days exclusion criteria: * previously received anti-pd-1, pd-l1, pd-l2, cd137, ctla-4 antibody treatment, or any other treatment that regulates t cells * received systemic corticosteroid or immunosuppressive therapy within 28 days before enrollment * complicated with autoimmune diseases or having a history of chronic or recurrent autoimmune diseases * history of pleural or pericardial adhesions within 28 days before enrollment * hiv antibody, htv-ⅰantibody, hcv antibody, hepatitis b surface protein antigen, hepatitis b surface protein antibody, hepatitis b core protein antibody or any detectable hepatitis b virus dna test results were positive * multiple primary cancers (excluding completely resected basal cell carcinoma, stage i squamous cell carcinoma, carcinoma in situ, intramucosal carcinoma, superficial bladder cancer, and any other cancer that has not recurred for at least 5 years) * brain or meningeal metastasis (unless asymptomatic and does not require treatment) * uncontrollable or serious cardiovascular disease.

Keywords: hepatocellular carcinoma sintilimab bevacizumab
hypotension decision assist - use, safety and efficacy

Conditions: Intraoperative Hypotension

Summary: this clinical investigation will investigate whether hypotension decision assist (hda) is a feasible, safe and effective patient clinical decision support system to enhance an anaesthetist's ability to manage a patient's cardiovascular system when undergoing surgery. if successful, this study will provide evidence that the use of hda facilitates beneficial outcomes for patients who have this device used.

in this study participants who are due to undergo elective major surgery and have an arterial line as part of their standard care will be invited to have the additional monitoring device (hda) included as part of their care. agreeing participants will have demographic, contact and medical history information necessary to conduct the study recorded, including a record of their intraoperative arterial line measurements. after completing the consent process participants will receive intraoperative monitoring with hypotension decision assist in addition to their standard care. the hda monitor will be attached to the patient vital signs monitor, which will in turn be attached to the blood pressure transducer. all sampled arterial line data collected by the patient vital signs monitored will be automatically transmitted in real time to the hda device via a serial cable attached to a digital export port of the vital signs monitor. hda will process this input data to display, in graphical and numeric format, vital signs data and physiological parameters derived from the arterial wave form data including: mean arterial pressure (map), systolic and diastolic blood pressure, heart rate and changes in heart rate, cardiac output and systemic vascular resistance. the output from the study will be compared to the primary and secondary outcomes to evaluate the performance and safety of the device and to evaluate whether hda improves control of the cardiovascular system from the anaesthetists' perspective.

Eligibility criteria:
inclusion criteria: * adults (≥18 years) due to undergo elective surgery who are likely to have an arterial line sited as part of their standard intraoperative care. * recruitment after booking for surgery with sufficient time to read, understand and question study patient information prior to attending for surgery. * ability and willingness to provide informed consent * expected duration of anaesthesia \> 60 minutes * intra-arterial monitoring is part of routine clinical care exclusion criteria: * inability to provide informed consent * no arterial line planned as part of their intraoperative care * aged \< 18 years of age * patients with aortic regurgitation * patients fitted with an intra-aortic balloon pump (iabp) * no other intra-arterial pressure management system in use * concurrent participation in another experimental intervention or drug study

Keywords: hypotension intraoperative care intraoperative complications
breast cancer study of stereotactic body radiation therapy (sbrt) combined neoadjuvant treatment

Conditions: Breast Cancer

Summary: the study is being conducted to evaluate the efficacy and safety of stereotactic body radiation therapy (sbrt) combined neoadjuvant treatment for patients with triple-negative and hormone receptor-positive, her2-negative breast cancer


Eligibility criteria:
inclusion criteria: * confirmed histologic diagnosis of invasive adenocarcinoma of the breast * er, pr and her2 testing, and * tnbc patients （ her2-neu 0-1+ by ihc or fish-negative by asco cap guidelines） * er-positive and her2-negative breast cancer * tumor measuring ≥2 cm in maximal diameter as measured by any available standard of care imaging (mammogram, breast ultrasound, breast mri) * any nodal status * ecog performance status of 0 -1 * screening laboratory values must meet the following criteria: i. absolute neutrophil count (anc) ≥1.5 × 109/l ii. platelets ≥100 × 109/l iii. hemoglobin ≥ 10.0 g/dl for tnbc, ≥ 10.0 g/dl for hr+/her2-bc iv. serum creatinine ≤1.5 x upper limit of normal (uln) v. ast ≤ 2.5 xuln vi. alt ≤ 2.5 x uln vii. total bilirubin ≤ 2.5 xuln viii left ventricular ejection fraction ≥ 50%. exclusion criteria: * any kind of prior treatment for breast cancer, including chemotherapy, radiotherapy, endocrine therapy and so on * inflammatory breast cancer * pregnant and lactating women; * distant metastasis * patients who have participated in other clinical trials.

Keywords: breast cancer
mindfulness for medical students

Conditions: Mindfulness; Burnout, Professional

Summary: burnout is common among medical students. previous studies had shown that mindfulness based interventions may improve burnout and quality of life in medical students. mindfulness-based cognitive therapy (mbct) is one of the most often used mindfulness based interventions. medical students in the chinese university of hong kong are invited to a mbct on voluntary basis. they will be asked to fill in questionnaire that measures burnout, depression/anxiety, quality of life, and mindfulness at beginning and end of the mbct. the pre-group and post-group data will be compared and analysed


Eligibility criteria:
inclusion criteria: * medical students studying in chinese university of hong kong exclusion criteria: * the investigators did not set any exclusion criteria
self-adherent wrap techniques for orbital surgery

Conditions: Surgery; Eye Diseases

Summary: the purpose of this study is to evaluate the interface pressure measurements of applying self-adherent wraps on eyes after orbital tumour extirpation.

the purpose of this study is to evaluate the interface pressure measurements of the folded and classic techniques of applying self-adherent wraps on eyes after orbital tumour extirpation.

Eligibility criteria:
inclusion criteria: * over 16 years old * diagnosed as orbital disease or ocular tumor * surgery under general anesthesia exclusion criteria: * any uncontrolled clinical problems

Keywords: general anesthesia self-adherent wrap pressure
interest of a systematic one-year monitoring by 18f-fdg pet-ct

Conditions: Malignant Lymphoma; Relapsed Non Hodgkin Lymphoma; Relapsed Hodgkin's Disease, Adult; Diagnostic Imaging

Summary: in the study, we aimed to characterize the role of fdg pet/ct surveillance at 12 months of malignant lymphoma in asymptomatic patients after a first complete remission and to define a rational follow-up strategy.

most aggressive lymphomas are sensitive to first-line immunochemotherapy and are in first complete remission (cr) with initial therapy. cr significantly decreases the risk of recurrence and increases survival. however, a cure is not guaranteed and approximately one third of lymphoma patients have a relapse disease. fdg pet/ct is a valuable noninvasive tool in the evaluation of lymphomas, especially to differentiate viable lymphoma and fibrosis or necrosis in residual mass. the majority of relapses are diagnosed based on clinical symptoms reported by patients. and the role of fdg pet/ct for routine surveillance of patients after treatment is controversial. however, many medical centers use routine follow-up fdg pet/ct in addition to physical examination and laboratory analysis to detect subclinical relapse. thus, we can imagine a good timing to routine fdg pet/ct when the tumor burden is small in the asymptomatic window. survival improvement for relapse detected by routine follow-up imaging is not clearly established compared to diagnosis by clinical symptoms. several studies tried to assess the value of follow-up fdg pet/ct but population, type, timing and duration of surveillance imaging was very heterogeneous.

Eligibility criteria:
inclusion criteria: * first diagnosis of aggressive lymphoma, complete metabolic remission after a first-line of chemotherapy, no relapse in the first year after the end of treatment exclusion criteria: * minor patient, pregnant woman, legal protection (legal curatorship / guardianship), absence of consent

Keywords: aggressive non-hodgkin lymphoma hodgkin lymphoma fdg-pet/ct follow-up routine surveillance
envelop: wound care following pilonidal sinus surgery

Conditions: Pilonidal Sinus; Wound Healing

Summary: this is a single-blinded, multicentre, prospective randomised controlled trial (rct) comparing post-operative and patient-reported outcomes for patients undergoing application of negative-pressure wound therapy (npwt) after sinus tract excision as compared to excision and standard open wound care in chronic pilonidal sinus disease (psd).

pilonidal sinus disease (psd) is a chronic inflammatory condition of the skin and subcutaneous tissues arising from hair follicles in the natal cleft. the definitive aetiology of the condition is unknown, however, it is theorised that it is the result of either the obstruction and subsequent inflammation of hair follicles or secondary to hair penetrating through the skin into the subcutaneous tissue. this results in infection, abscess formation, chronic discharge and pain. psd is a common condition affecting 26 per 10,000 population, with the prevalence reaching 1.1% in young adult males. psd causes a significant burden on healthcare services due to high rates of recurrence and readmission following surgery, together with negative impacts on patients' quality of life and self-image. an effective management strategy for the disease is necessary to ensure that post-operative outcomes are optimised and patient-reported outcomes are satisfactory in those whose psd requires surgery. the objective of this multicentre, national rct is to prospectively investigate the effect of negative pressure wound therapy compared to leaving open with standard wound care on time to wound healing following surgical excision of chronic psd.

Eligibility criteria:
inclusion criteria: i) they are aged 18 years or older ii) they are undergoing elective pilonidal sinus excision without primary closure exclusion criteria: i) they are unable to adhere to protocol requirements e.g. questionnaire completion ii) they are undergoing emergency drainage for a pilonidal abscess iii) they are undergoing surgery for a pilonidal sinus disease in locations other than the natal cleft iv) they have underlying osteomyelitis v) they have underlying fistulating disease e.g. crohn's

Keywords: negative pressure wound therapy surgical site infection post-operative complications health economics posas copaq eq-5d-5l pain score
preoperative chemoradiotherapy versus chemotherapy alone in nonsmall cell lung cancer (nsclc) patients with mediastinal lymph node metastases

Conditions: Non-small Cell Lung Cancer

Summary: the main objective of this trial is to compare feasibility and efficacy of sequential neoadjuvant chemoradiotherapy with 44gy concomitant boost to neoadjuvant chemotherapy alone. secondary objectives are to assess the value of position emission tomography (pet）in predicting pathological response and event-free survival（efs）in stage iiia non-small cell lung cancer (nsclc). further to compare the amount of serum dna in patients with stage iiia nsclc before, during and after chemotherapy, before and after radiotherapy (in arm a) and during follow-up in patients randomized into the trial and to correlate the deoxyribonucleic acid (dna) variation with tumor response, remission duration and overall survival.


Eligibility criteria:
inclusion criteria: * histologically proven nsclc with nodal metastases: t1-3n2m0 * performance status 0-1 * patient medically fit enough for protocol therapy, including operability * age 18-75 * written informed consent * no previous chemo- or radiotherapy exclusion criteria: * patients with prior or concomitant malignancies allowed are: non-melanomatous skin cancer, adequately treated in situ cervical cancer or any other neoplastic diseases with disease-free interval ³ 5 years. * presence or history of any distant metastasis * unstable cardiac disease requiring treatment, congestive heart failure or angina pectoris even if medically controlled, significant arrhythmia, or prior history of myocardial infarction in the last 3 months * history of significant neurologic or psychiatric disorders including psychotic disorders, dementia or seizures that would prohibit the understanding and giving of informed consent * active uncontrolled infection * uncontrolled diabetes mellitus * gastric ulcers * preexisting peripheral neuropathy (\> grade 1) * other serious underlying medical condition which could impair the ability of the patient to participate in the trial * concurrent treatment with other experimental drugs * pretreatment with any other cytostatic therapy * previous radiotherapy to the chest * concurrent treatment with prednisone (or equivalent) except: for the prophylactic medication regimen before treatment, treatment of acute hypersensitivity reactions or chronic treatment (initiated \> 6 months prior to trial entry) at low dose (£ 20 mg methylprednisolone or equivalent) * definite contraindications for the use of corticosteroids as premedication * treatment within a clinical trial within 30 days prior to trial entry * socioeconomic or geographic circumstances that may prohibit proper staging, treatment or follow-up procedures * pregnancy, lactation period

Keywords: preoperative chemoradiotherapy stage iiia, n2
urine sample collection for validation of the anchordx urifind™ bladder cancer assay

Conditions: Bladder Cancer

Summary: the anchordx urifind™ bladder cancer assay is designed to detect 2 dna methylation biomarkers in urine specimens from patients 22 years or older suspected of having bladder cancer. results from the assay are intended for use, in conjunction with current standard diagnostic procedures, as an aid for initial diagnosis of bladder carcinoma in patients.


Eligibility criteria:
inclusion criteria: clinical validation group: 1. 55 years or older, gender is not limited 2. suspected of bladder cancer and are scheduled for bladder biopsy or trans-uretheral resection of bladder tumor (tubrt) 3. can receive standard of care, including urine cytology, cystoscopy, or surgery for bladder cancer diagnosis 4. can provide at least of 75 ml of urine (prior to cystoscopy or surgery) exclusion criteria: 1. history of urinary cancer 2. neoadjuvant therapy
efficacy and safety in pacemaker and defibrillator implantation via cephalic versus axillary vein access (cephax)

Conditions: Pacemakers; Defibrillators; Complication; Pacemaker Electrode Lead Fracture

Summary: this clinical trial evaluates the efficacy and safety of axillary versus cephalic venous access in the pacemakers and defibrillators implantation. half of participants will receive the implant via fluoroscopy guided axillary venous access and the other half will receive the implant via improved cephalic venous access.


Eligibility criteria:
inclusion criteria: * patients with a endovenous pacemaker or defibrillator indication. exclusion criteria: * pre-existing ipsilateral pacing electrode. * previous ipsilateral lymphadenectomy. * indication of cardiac resynchronization therapy.

Keywords: cephalic vein axillary vein
endothelial function and vein graft remodeling

Conditions: Peripheral Arterial Disease; Cardiovascular Disease

Summary: the purpose of this study is to better understand why some vein bypass grafts develop narrowing. evidence suggests that there is a relationship between inflammatory markers in the blood and the narrowing that occurs in blood vessels. in this study, we will look at inflammatory markers in the blood and how well the vein graft functions.

despite the acceptance of catheter-based approaches to lower extremity reconstruction, bypass with autogenous vein remains the most durable option. in the united states alone there are approximately 100,000 lower extremity bypass procedures performed yearly. however, 30-50% of these grafts either occlude or require revision in the first 5 years. traditional framingham cardiovascular risk factors such as dyslipidemia and diabetes do not predict which grafts are at risk for failure. therefore other variables such as hemodynamic factors or endothelial function may be important in identifying vulnerable vein grafts. the applicant has previously noted that vein grafts undergo dramatic geometric remodeling within the first month after implantation into the arterial circulation. this is partly driven by hemodynamic forces such as shear stress and is thought to be related to endothelial function. shear stress is positively correlated with early (0-1 month) luminal enlargement. this adaptive response is important to maintain bypass graft patency. however, there is considerable amount of variability in this response unaccounted for by shear stress alone. the applicant has further shown that baseline systemic inflammation dampens the ability for adequate vein graft luminal expansion and therefore may uncouple the mechano-chemical signal transduction at the endothelial level. therefore, this study will examine the relationship between circulating levels of inflammatory mediators and endothelial function in a cohort of patients undergoing lower extremity arterial reconstruction with autogenous vein.

Eligibility criteria:
inclusion criteria: * age \> 22 or \< 90 years * undergoing lower extremity (infrainguinal) bypass using autologous vein for the treatment of disabling claudication or critical limb ischemia secondary to chronic atherosclerotic occlusive disease * able to understand, give, and take part in the consent process exclusion criteria: * age \ 90 years * grafts employing prosthetic or other non-autologous vein material in any part (e.g. composite grafts). \[patch angioplasty of inflow and outflow vessel permissible with any material\] * vasculitis, trauma, acute embolic disease as etiology of limb ischemia * history of diagnosed hypercoagulable state * evidence of active infection - pneumonia, urinary tract, etc., requiring medical therapy * evidence of significant local sepsis in foot or limb prior to bypass * patients taking immunosuppressant medications (steroids, chemotherapeutic agents) * other concurrent significant illness within 30 days * non-english speakers